Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?
Sign Up to like & getrecommendations! Published in 2017 at "Cell Cycle"
DOI: 10.1080/15384101.2016.1247568
Abstract: The approval of multitargeted anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has been a success story for the management of advanced non-small-cell lung cancers (NSCLCs) over the last half a decade, with the 1st… read more here.
Keywords: alk inhibitors; resistance alk; alk; kinase ... See more keywords
Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2020.1721285
Abstract: ABSTRACT Introduction: ALK rearrangements are present in 2-7% of non-small cell lung cancer (NSCLC) cases, where the EML4-ALK fusion is the most frequent. Rearrangement of ALK with other fusion partners occurs only in ≈5% of… read more here.
Keywords: alk inhibitors; resistance alk; alk; non small ... See more keywords
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020008136
Abstract: Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance… read more here.
Keywords: ptpn1 ptpn2; resistance alk; resistance; alk ... See more keywords